What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals (ALNY) generated $4.8B in revenue over the trailing twelve months, up 95.1% year over year.

Is Alnylam Pharmaceuticals profitable?

Alnylam Pharmaceuticals reported $733.1M in net income over the trailing twelve months, a 15.3% net margin.

What are Alnylam Pharmaceuticals's profit margins?

Gross margin is 79.8% and operating margin is 20.8%, with a 15.3% net margin.

What is Alnylam Pharmaceuticals's earnings per share?

Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $5.38.

Where does Alnylam Pharmaceuticals's income statement data come from?

Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q2 '26	Q1 '26	Q4 '25	Q3 '25	Q2 '25
Total revenue	$1.29B+66.9%	$1.17B+96.4%	$1.1B+84.9%	$1.25B+149%	$773.69M+17.3%
Total cost of revenue	$298.26M+110%	$207.52M+196%	$267.72M+161%	$197.23M+141%	$142.03M+111%
Gross profit	$992.69M+57.2%	$959.66M+83.1%	$829.31M+69.1%	$1.05B+151%	$631.66M+6.6%
Gross margin	76.9%-4.7pp	82.2%-6.0pp	75.6%-7.1pp	84.2%+0.6pp	81.6%-8.2pp
Research and development	$413.13M+27.7%	$364.87M+37.6%	$372.22M+24.0%	$358.81M+32.4%	$323.62M+10.0%
Selling, general and administrative	$347.92M+7.6%	$322.55M+34.4%	$325.37M+10.2%	$322.08M+45.7%	$323.31M+30.2%
Total costs & expenses	$1.06B+34.1%	$898.54M+56.0%	$965.32M+38.2%	$881.04M+52.5%	$789.89M+29.2%
Operating income	$231.44M+1,529%	$268.64M+1,386%	$131.72M+225%	$367.98M+578%	-$16.2M-133%
Operating margin	17.9%+20.0pp	23%+20.0pp	12%+29.7pp	29.5%+44.8pp	-2.1%-9.5pp
Interest expense	$82.05M+104%	$69.29M+18.8%	$65.4M+67.8%	$44.4M+29.2%	$40.25M+21.0%
Other income (expense), net	-$53.64M-180%	-$46.98M-130%	-$45.46M+48.8%	-$129.01M-306%	-$19.16M+68.0%
Income before income taxes	$177.81M+603%	$221.65M+9,460%	$86.26M+144%	$238.97M+320%	-$35.36M-217%
Income tax expense	$13.31M-56.9%	$15.66M-1.4%	——	-$12.12M-517%	$30.92M+440%
Net income	$164.49M+348%	$205.99M+1,229%	$111.54M+233%	$251.08M+325%	-$66.28M-292%
Net margin	12.7%+21.3pp	17.6%+20.7pp	10.2%+24.3pp	20.1%+42.4pp	-8.6%-6.0pp
Diluted earnings per share	$1.21+337%	$1.51+1,179%	$0.82+226%	$1.84+311%	-$0.51-292%
EBITDA	$245.34M+10,980%	$282.19M+769%	$145.22M+260%	$381.79M+707%	-$2.26M-104%
EBITDA margin	19%+19.3pp	24.2%+18.7pp	13.2%+28.6pp	30.6%+43.1pp	-0.3%-9.9pp
EBIT	$231.44M+1,529%	$268.64M+1,386%	$131.72M+225%	$367.98M+578%	-$16.2M-133%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's revenue?: Alnylam Pharmaceuticals (ALNY) generated $4.8B in revenue over the trailing twelve months, up 95.1% year over year.
Is Alnylam Pharmaceuticals profitable?: Alnylam Pharmaceuticals reported $733.1M in net income over the trailing twelve months, a 15.3% net margin.
What are Alnylam Pharmaceuticals's profit margins?: Gross margin is 79.8% and operating margin is 20.8%, with a 15.3% net margin.
What is Alnylam Pharmaceuticals's earnings per share?: Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $5.38.
Where does Alnylam Pharmaceuticals's income statement data come from?: Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.